/
BIVI
$2.01+$0.07 (+3.61%)live
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$14.6M
8M shares
52-week range
$1.06 – $10.30
10% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Price (6 mo)
Loading chart…
Change$-1692.99
BioVie, Inc. Common Stock
BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.
www.bioviepharma.com- Employees
- 13
- IPO / List date
- Jan 14, 2014
- HQ
- CARSON CITY, NV
Held by traders on TradeandTell
No one on the platform currently holds BIVI.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 67,918 | $95.1K |
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2025-07-07 | 1-for-10reverse |
| 2024-08-06 | 1-for-10reverse |
| 2019-11-22 | 1-for-125reverse |
Recent trades on TradeandTell
No one on the platform has traded BIVI yet.
